Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Stress-induced alterations in parkin solubility promote parkin aggregation and compromise parkin's protective function.

Wang C, Ko HS, Thomas B, Tsang F, Chew KC, Tay SP, Ho MW, Lim TM, Soong TW, Pletnikova O, Troncoso J, Dawson VL, Dawson TM, Lim KL.

Hum Mol Genet. 2005 Dec 15;14(24):3885-97. Epub 2005 Nov 8.

PMID:
16278233
2.

Phosphorylation by the c-Abl protein tyrosine kinase inhibits parkin's ubiquitination and protective function.

Ko HS, Lee Y, Shin JH, Karuppagounder SS, Gadad BS, Koleske AJ, Pletnikova O, Troncoso JC, Dawson VL, Dawson TM.

Proc Natl Acad Sci U S A. 2010 Sep 21;107(38):16691-6. doi: 10.1073/pnas.1006083107. Epub 2010 Sep 7.

3.

Formation of parkin aggregates and enhanced PINK1 accumulation during the pathogenesis of Parkinson's disease.

Um JW, Park HJ, Song J, Jeon I, Lee G, Lee PH, Chung KC.

Biochem Biophys Res Commun. 2010 Mar 19;393(4):824-8. doi: 10.1016/j.bbrc.2010.02.090. Epub 2010 Feb 18.

PMID:
20171192
4.

Familial-associated mutations differentially disrupt the solubility, localization, binding and ubiquitination properties of parkin.

Sriram SR, Li X, Ko HS, Chung KK, Wong E, Lim KL, Dawson VL, Dawson TM.

Hum Mol Genet. 2005 Sep 1;14(17):2571-86. Epub 2005 Jul 27.

PMID:
16049031
5.

Parkin and defective ubiquitination in Parkinson's disease.

Dawson TM.

J Neural Transm Suppl. 2006;(70):209-13. Review.

PMID:
17017531
6.

Parkin is recruited into aggresomes in a stress-specific manner: over-expression of parkin reduces aggresome formation but can be dissociated from parkin's effect on neuronal survival.

Muqit MM, Davidson SM, Payne Smith MD, MacCormac LP, Kahns S, Jensen PH, Wood NW, Latchman DS.

Hum Mol Genet. 2004 Jan 1;13(1):117-35. Epub 2003 Nov 25.

PMID:
14645198
7.

S-nitrosylation of parkin regulates ubiquitination and compromises parkin's protective function.

Chung KK, Thomas B, Li X, Pletnikova O, Troncoso JC, Marsh L, Dawson VL, Dawson TM.

Science. 2004 May 28;304(5675):1328-31. Epub 2004 Apr 22.

8.

Relative sensitivity of parkin and other cysteine-containing enzymes to stress-induced solubility alterations.

Wong ES, Tan JM, Wang C, Zhang Z, Tay SP, Zaiden N, Ko HS, Dawson VL, Dawson TM, Lim KL.

J Biol Chem. 2007 Apr 20;282(16):12310-8. Epub 2007 Feb 28.

9.

Alterations in the solubility and intracellular localization of parkin by several familial Parkinson's disease-linked point mutations.

Wang C, Tan JM, Ho MW, Zaiden N, Wong SH, Chew CL, Eng PW, Lim TM, Dawson TM, Lim KL.

J Neurochem. 2005 Apr;93(2):422-31.

10.

The role of parkin in familial and sporadic Parkinson's disease.

Dawson TM, Dawson VL.

Mov Disord. 2010;25 Suppl 1:S32-9. doi: 10.1002/mds.22798. Review.

11.

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease.

Lo Bianco C, Schneider BL, Bauer M, Sajadi A, Brice A, Iwatsubo T, Aebischer P.

Proc Natl Acad Sci U S A. 2004 Dec 14;101(50):17510-5. Epub 2004 Dec 2.

12.

[Etiology and pathogenesis of Parkinson's disease: from mitochondrial dysfunctions to familial Parkinson's disease].

Hattori N.

Rinsho Shinkeigaku. 2004 Apr-May;44(4-5):241-62. Review. Japanese.

PMID:
15287506
13.

Nitrosative stress linked to sporadic Parkinson's disease: S-nitrosylation of parkin regulates its E3 ubiquitin ligase activity.

Yao D, Gu Z, Nakamura T, Shi ZQ, Ma Y, Gaston B, Palmer LA, Rockenstein EM, Zhang Z, Masliah E, Uehara T, Lipton SA.

Proc Natl Acad Sci U S A. 2004 Jul 20;101(29):10810-4. Epub 2004 Jul 13. Erratum in: Proc Natl Acad Sci U S A. 2004 Sep 21;101(38):13969.

14.

Parkin protects human dopaminergic neuroblastoma cells against dopamine-induced apoptosis.

Jiang H, Ren Y, Zhao J, Feng J.

Hum Mol Genet. 2004 Aug 15;13(16):1745-54. Epub 2004 Jun 15.

PMID:
15198987
15.

Elevated TRAF2/6 expression in Parkinson's disease is caused by the loss of Parkin E3 ligase activity.

Chung JY, Park HR, Lee SJ, Lee SH, Kim JS, Jung YS, Hwang SH, Ha NC, Seol WG, Lee J, Park BJ.

Lab Invest. 2013 Jun;93(6):663-76. doi: 10.1038/labinvest.2013.60. Epub 2013 Apr 22.

16.

Genetics of parkin-linked disease.

West AB, Maidment NT.

Hum Genet. 2004 Mar;114(4):327-36. Epub 2004 Jan 15. Review.

PMID:
14727181
17.

Parkin: much more than a simple ubiquitin ligase.

Alves da Costa C, Checler F.

Neurodegener Dis. 2012;10(1-4):49-51. doi: 10.1159/000332803. Epub 2011 Dec 23. Review.

PMID:
22204976
18.

Parkin loss of function contributes to RTP801 elevation and neurodegeneration in Parkinson's disease.

Romaní-Aumedes J, Canal M, Martín-Flores N, Sun X, Pérez-Fernández V, Wewering S, Fernández-Santiago R, Ezquerra M, Pont-Sunyer C, Lafuente A, Alberch J, Luebbert H, Tolosa E, Levy OA, Greene LA, Malagelada C.

Cell Death Dis. 2014 Aug 7;5:e1364. doi: 10.1038/cddis.2014.333.

19.

New insights into Parkinson's disease.

Chung KK, Dawson VL, Dawson TM.

J Neurol. 2003 Oct;250 Suppl 3:III15-24. Review.

PMID:
14579120
20.

Dopamine covalently modifies and functionally inactivates parkin.

LaVoie MJ, Ostaszewski BL, Weihofen A, Schlossmacher MG, Selkoe DJ.

Nat Med. 2005 Nov;11(11):1214-21. Epub 2005 Oct 16.

PMID:
16227987

Supplemental Content

Support Center